Drug Type Polymer |
Synonyms Firtecan pegol (USAN/INN), BEL-0222, EZN-2208 + [3] |
Target |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC118H122N12O37 |
InChIKeyCXWRXYDTWCBSJF-UHFFFAOYSA-N |
CAS Registry946062-05-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapsed Solid Neoplasm | Phase 2 | US | 01 Feb 2010 | |
Metastatic breast cancer | Phase 2 | US | 01 Nov 2009 | |
Metastatic Colorectal Carcinoma | Phase 2 | US | 01 Jun 2009 | |
Metastatic Colorectal Carcinoma | Phase 2 | CA | 01 Jun 2009 | |
Metastatic Colorectal Carcinoma | Phase 2 | IL | 01 Jun 2009 | |
Metastatic Colorectal Carcinoma | Phase 2 | NL | 01 Jun 2009 | |
Metastatic Colorectal Carcinoma | Phase 2 | GB | 01 Jun 2009 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 01 May 2007 | |
Lymphoma | Phase 1 | US | 01 May 2007 |
Phase 2 | Metastatic breast cancer Adjuvant | 164 | jfdvpjwmhy(yewmyalumv) = kggvdscutf unolwukkjf (buelaldvfg ) View more | - | 20 May 2012 |